Invention Grant
- Patent Title: Platform of dendritic cell (DC)-based vaccination
- Patent Title (中): 基于树突状细胞(DC)的疫苗接种平台
-
Application No.: US13750850Application Date: 2013-01-25
-
Publication No.: US08691570B2Publication Date: 2014-04-08
- Inventor: Pawel Kalinski
- Applicant: Pawel Kalinski
- Agency: Klarquist Sparkman, LLP
- Main IPC: C12N5/071
- IPC: C12N5/071 ; C12N5/00 ; C12N5/02

Abstract:
The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.
Public/Granted literature
- US20130130380A1 PLATFORM OF DENDRITIC CELL (DC)-BASED VACCINATION Public/Granted day:2013-05-23
Information query